



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

September 2016





HIV/AIDS Drug Treatment Program

Monthly Report

© 2016 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

September 2016

N = 7103



Health Authority	Male	Female	All
FRASER	1350	383	1733
INTERIOR	363	92	455
NORTHERN	137	74	211
VANCOUVER COASTAL	3370	446	3816
VANCOUVER ISLAND	697	162	859
	5917	1157	7074
		Unknown/not stated:	29
		Total:	7103

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (September 2011 - September 2016)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (September 2011 - September 2016)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (September 2011 - September 2016)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (September 2011 - September 2016)






1.6 Percent Distribution of Active Participants by CD4 Count
(September 2011 - September 2016)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(September 2011 - September 2016)






1.8 Active and Inactive Participants (September 2011 - September 2016)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (September 2011 - September 2016)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (September 2011 - September 2016)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(September 2011 - September 2016)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (September 2011 - September 2016)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(September 2011 - September 2016)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (September 2011 - September 2016)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(September 2011 - September 2016)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (September 2011 - September 2016)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(September 2011 - September 2016)






1.18 Baseline CD4 for Antiretroviral First Starts (September 2011 - September 2016)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(September 2011 - September 2016)**






1.20 Cumulative Resistance Testing Results by Resistance Category (September 2011 - September 2016)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (September 2011 - September 2016)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2016
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	24	5	0	5	4	810	4	<40	3
1988	24	7	0	7	7	570	7	<40	3
1989	23	55	2	57	48	510	54	<40	3
1990	22	61	1	62	59	570	61	<40	3
1991	22	38	3	41	33	520	39	<40	3
1992	22	69	5	74	57	580	72	<40	3
1993	21	144	15	159	146	575	155	<40	3
1994	20	95	14	109	90	540	103	<40	3
1995	20	126	22	148	126	550	138	<40	3
1996	18	362	59	421	361	620	403	<40	3
1997	16	299	39	338	299	620	322	<40	3
1998	15	219	48	267	230	560	255	<40	3
1999	15	184	41	225	195	570	212	<40	3
2000	15	138	39	177	155	610	171	<40	3
2001	15	134	36	170	146	545	157	<40	3
2002	14	142	30	172	149	550	166	<40	3
2003	13	170	33	203	179	590	194	<40	3
2004	12	181	42	223	189	590	209	<40	3
2005	11	206	51	257	212	625	239	<40	3
2006	10	210	44	254	206	580	237	<40	3
2007	9	275	54	329	288	605	315	<40	3
2008	8	305	72	377	322	610	354	<40	3
2009	7	346	75	421	362	645	405	<40	3
2010	6	310	73	383	329	630	359	<40	3
2011	5	364	70	434	373	660	409	<40	3
2012	4	292	65	357	308	680	339	<40	3
2013	3	287	67	354	296	645	341	<40	3
2014	2	311	55	366	298	686	345	<40	3
2015	1	343	53	396	336	610	375	<40	3
2016	0	249	47	296	275	510	281	<40	3
Total:		5927	1155	7082					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	6739	760	2430	<40	2189	580
FEB-2015	6787	754	1976	<40	1779	580
MAR-2015	6834	748	2173	<40	1973	570
APR-2015	6845	739	2150	<40	1971	580
MAY-2015	6881	740	2032	<40	1842	560
JUN-2015	6897	740	2254	<40	2044	580
JUL-2015	6924	739	2037	<40	1853	580
AUG-2015	6922	752	2075	<40	1831	580
SEP-2015	6922	749	2265	<40	2059	580
OCT-2015	6957	740	2100	<40	1878	590
NOV-2015	7008	722	2064	<40	1875	580
DEC-2015	6988	725	2015	<40	1830	600
JAN-2016	6974	737	2264	<40	2019	590
FEB-2016	6993	735	2066	<40	1864	590
MAR-2016	6998	737	2155	<40	1956	590
APR-2016	7018	734	2054	<40	1861	580
MAY-2016	7050	747	2074	<40	1872	590
JUN-2016	7071	739	2181	<40	1965	610
JUL-2016	7065	749	1949	<40	1732	600
AUG-2016	7078	750	2068	<40	1788	600
SEP-2016	7103	753	2211	<40	1902	600

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2015	1513	2042	104	1325	89	340
FEB-2015	1497	2111	103	75	89	380
MAR-2015	1469	2260	101	56	95	410
APR-2015	1475	2244	83	2239	73	460
MAY-2015	1460	2339	73	148	65	380
JUN-2015	1477	2263	96	106	92	420
JUL-2015	1470	2326	71	598	60	380
AUG-2015	1480	2303	82	2341	77	440
SEP-2015	1504	2231	91	128	85	360
OCT-2015	1486	2347	81	<40	70	405
NOV-2015	1463	2458	85	169	78	400
DEC-2015	1500	2312	79	344	64	330
JAN-2016	1512	2286	114	<40	102	470
FEB-2016	1504	2348	80	751	71	380
MAR-2016	1512	2315	87	130	83	440
APR-2016	1515	2319	86	<50	72	355
MAY-2016	1497	2403	76	<40	67	350
JUN-2016	1506	2403	70	61	54	510
JUL-2016	1529	2339	82	74	75	430
AUG-2016	1558	2230	94	118	76	400
SEP-2016	1568	2228	100	192	82	410

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2015	6706	1513	13	24	149	188	-35	11954
FEB-2015	6756	1497	7	36	187	163	50	12006
MAR-2015	6809	1469	7	29	177	144	53	12046
APR-2015	6808	1475	15	28	168	172	-1	12082
MAY-2015	6846	1460	9	33	170	150	38	12123
JUN-2015	6869	1477	5	36	153	159	23	12170
JUL-2015	6905	1470	5	25	167	149	36	12208
AUG-2015	6903	1480	7	19	145	156	-2	12238
SEP-2015	6898	1504	9	32	157	180	-5	12279
OCT-2015	6926	1486	14	24	171	147	28	12316
NOV-2015	6977	1463	9	29	183	150	51	12357
DEC-2015	6954	1500	11	21	153	182	-23	12389
JAN-2016	6944	1512	9	16	154	168	-10	12410
FEB-2016	6966	1504	5	18	177	162	22	12438
MAR-2016	6973	1512	9	24	168	172	7	12472
APR-2016	6995	1515	6	20	167	157	22	12506
MAY-2016	7029	1497	7	24	160	142	34	12537
JUN-2016	7047	1506	12	34	161	163	18	12580
JUL-2016	7040	1529	10	26	135	154	-7	12613
AUG-2016	7054	1558	10	40	163	174	14	12673
SEP-2016	7082	1568	4	27	179	170	28	12716

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2015	48	6180	440	74	6742	0.71%	91.66%	6.53%	1.10%	100.00%
FEB-2015	49	6219	451	73	6792	0.72%	91.56%	6.64%	1.07%	100.00%
MAR-2015	47	6287	436	67	6837	0.69%	91.96%	6.38%	0.98%	100.00%
APR-2015	47	6296	435	67	6845	0.69%	91.98%	6.36%	0.98%	100.00%
MAY-2015	49	6334	431	68	6882	0.71%	92.04%	6.26%	0.99%	100.00%
JUN-2015	51	6329	446	72	6898	0.74%	91.75%	6.47%	1.04%	100.00%
JUL-2015	46	6359	453	67	6925	0.66%	91.83%	6.54%	0.97%	100.00%
AUG-2015	49	6359	444	70	6922	0.71%	91.87%	6.41%	1.01%	100.00%
SEP-2015	49	6370	439	64	6922	0.71%	92.03%	6.34%	0.92%	100.00%
OCT-2015	52	6399	442	64	6957	0.75%	91.98%	6.35%	0.92%	100.00%
NOV-2015	57	6439	445	67	7008	0.81%	91.88%	6.35%	0.96%	100.00%
DEC-2015	53	6425	448	62	6988	0.76%	91.94%	6.41%	0.89%	100.00%
JAN-2016	55	6410	448	61	6974	0.79%	91.91%	6.42%	0.87%	100.00%
FEB-2016	58	6439	437	59	6993	0.83%	92.08%	6.25%	0.84%	100.00%
MAR-2016	54	6445	438	61	6998	0.77%	92.10%	6.26%	0.87%	100.00%
APR-2016	54	6465	442	57	7018	0.77%	92.12%	6.30%	0.81%	100.00%
MAY-2016	57	6500	439	54	7050	0.81%	92.20%	6.23%	0.77%	100.00%
JUN-2016	60	6508	447	56	7071	0.85%	92.04%	6.32%	0.79%	100.00%
JUL-2016	57	6509	442	57	7065	0.81%	92.13%	6.26%	0.81%	100.00%
AUG-2016	57	6519	447	55	7078	0.81%	92.10%	6.32%	0.78%	100.00%
SEP-2016	58	6541	447	57	7103	0.82%	92.09%	6.29%	0.80%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		emtricitabine		tenofovir <TAF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	10 29%	2583 40%	10 29%	2220 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3846 59%	0 0%	0 0%
FEB-2015	8 15%	2593 39%	8 15%	2228 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3878 59%	0 0%	0 0%
MAR-2015	10 25%	2610 39%	10 25%	2253 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3913 59%	0 0%	0 0%
APR-2015	10 29%	2626 40%	10 29%	2267 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3911 59%	0 0%	0 0%
MAY-2015	8 20%	2638 40%	7 18%	2280 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3922 59%	0 0%	0 0%
JUN-2015	10 21%	2633 39%	10 21%	2287 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3941 59%	0 0%	0 0%
JUL-2015	4 11%	2659 40%	4 11%	2313 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3944 59%	0 0%	0 0%
AUG-2015	12 40%	2675 40%	11 37%	2334 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 60%	3941 59%	0 0%	0 0%
SEP-2015	17 41%	2715 40%	15 37%	2373 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	24 59%	3911 58%	0 0%	0 0%
OCT-2015	11 30%	2747 41%	10 27%	2404 36%	0 0%	102 2%	0 0%	13 0%	0 0%	8 0%	26 70%	3901 58%	0 0%	0 0%
NOV-2015	17 41%	2785 41%	15 37%	2440 36%	1 2%	102 2%	0 0%	13 0%	0 0%	8 0%	24 59%	3910 58%	0 0%	0 0%
DEC-2015	5 16%	2793 41%	5 16%	2454 36%	0 0%	95 1%	0 0%	12 0%	0 0%	8 0%	27 84%	3883 57%	0 0%	0 0%
JAN-2016	4 19%	2819 42%	4 19%	2486 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	17 81%	3852 57%	0 0%	0 0%
FEB-2016	10 36%	2854 42%	9 32%	2522 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	18 64%	3830 57%	0 0%	0 0%
MAR-2016	9 26%	2878 43%	7 21%	2543 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	25 74%	3811 56%	0 0%	0 0%
APR-2016	12 35%	2894 43%	9 26%	2568 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	22 65%	3815 56%	0 0%	5 0%
MAY-2016	8 26%	2897 43%	8 26%	2581 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	23 74%	3838 56%	0 0%	6 0%
JUN-2016	11 26%	2928 43%	11 26%	2606 38%	0 0%	91 1%	0 0%	12 0%	0 0%	7 0%	32 74%	3834 56%	1 2%	9 0%
JUL-2016	9 27%	2906 43%	9 27%	2586 38%	0 0%	90 1%	0 0%	12 0%	0 0%	7 0%	24 73%	3840 56%	0 0%	9 0%
AUG-2016	11 19%	2939 43%	11 19%	2630 38%	0 0%	80 1%	0 0%	11 0%	0 0%	7 0%	48 81%	3837 56%	6 10%	22 0%
SEP-2016	14 33%	2967 43%	12 28%	2659 39%	0 0%	80 1%	0 0%	8 0%	0 0%	6 0%	29 67%	3844 56%	3 7%	25 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	tenofovir <TDF>			
	Initial		All	
JAN-2015	25	71%	4210	64%
FEB-2015	44	85%	4241	64%
MAR-2015	30	75%	4269	64%
APR-2015	24	69%	4267	64%
MAY-2015	33	83%	4276	64%
JUN-2015	37	79%	4292	64%
JUL-2015	34	89%	4294	64%
AUG-2015	18	60%	4281	64%
SEP-2015	24	59%	4251	63%
OCT-2015	27	73%	4239	63%
NOV-2015	25	61%	4242	63%
DEC-2015	27	84%	4208	62%
JAN-2016	17	81%	4169	62%
FEB-2016	18	64%	4137	61%
MAR-2016	26	76%	4114	61%
APR-2016	22	65%	4107	61%
MAY-2016	23	74%	4124	61%
JUN-2016	31	72%	4122	60%
JUL-2016	24	73%	4123	60%
AUG-2016	42	71%	4103	60%
SEP-2016	27	63%	4100	60%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	0 0%	12 0%	6 50%	2029 60%	6 50%	930 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2029 60%	18 69%	960 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2044 60%	8 47%	970 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 1%
APR-2015	0 0%	12 0%	7 33%	2025 60%	14 67%	988 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	1999 59%	6 38%	1018 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1965 58%	10 56%	1037 31%	0 0%	358 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1957 58%	11 79%	1050 31%	1 7%	351 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1946 58%	7 64%	1054 31%	3 27%	345 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 25%	1912 58%	11 69%	1060 32%	1 6%	338 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
OCT-2015	0 0%	10 0%	5 31%	1900 57%	10 63%	1087 33%	1 6%	331 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
NOV-2015	0 0%	10 0%	4 27%	1875 56%	9 60%	1107 33%	2 13%	329 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
DEC-2015	0 0%	11 0%	3 25%	1838 56%	8 67%	1118 34%	1 8%	328 10%	0 0%	4 0%	0 0%	1 0%	0 0%	17 1%
JAN-2016	0 0%	11 0%	5 45%	1822 55%	5 45%	1130 34%	1 9%	327 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1793 55%	6 46%	1157 35%	1 8%	318 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1770 55%	11 69%	1171 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1747 54%	13 93%	1198 37%	0 0%	294 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1731 53%	10 83%	1221 38%	0 0%	283 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%
JUN-2016	0 0%	8 0%	3 20%	1711 53%	12 80%	1238 38%	0 0%	284 9%	0 0%	4 0%	0 0%	1 0%	0 0%	15 0%
JUL-2016	0 0%	7 0%	4 27%	1694 53%	11 73%	1244 39%	0 0%	273 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
AUG-2016	0 0%	8 0%	3 10%	1667 52%	26 90%	1257 39%	0 0%	268 8%	0 0%	2 0%	0 0%	0 0%	0 0%	14 0%
SEP-2016	0 0%	8 0%	1 9%	1643 52%	9 82%	1272 40%	1 9%	260 8%	0 0%	3 0%	0 0%	1 0%	0 0%	14 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%
OCT-2015	0	0%	1	0%
NOV-2015	0	0%	1	0%
DEC-2015	0	0%	1	0%
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%
JUN-2016	0	0%	1	0%
JUL-2016	0	0%	1	0%
AUG-2016	0	0%	0	0%
SEP-2016	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	900 34%	2 25%	253 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	892 34%	4 50%	250 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	889 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1097 43%	1 11%	305 12%	0 0%	873 35%	0 0%	256 10%
OCT-2015	2 50%	1083 43%	0 0%	312 12%	1 25%	867 35%	1 25%	251 10%
NOV-2015	4 67%	1074 43%	0 0%	312 12%	0 0%	865 35%	2 33%	254 10%
DEC-2015	2 100%	1055 42%	0 0%	312 13%	0 0%	863 35%	0 0%	254 10%
JAN-2016	2 100%	1032 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	259 11%
MAR-2016	2 50%	997 41%	0 0%	307 13%	1 25%	854 35%	1 25%	258 11%
APR-2016	3 33%	991 41%	1 11%	308 13%	3 33%	845 35%	2 22%	260 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	834 35%	3 38%	260 11%
JUN-2016	4 67%	979 41%	0 0%	298 13%	0 0%	839 35%	2 33%	260 11%
JUL-2016	1 25%	970 41%	1 25%	299 13%	2 50%	837 35%	0 0%	257 11%
AUG-2016	5 71%	960 41%	0 0%	296 13%	0 0%	831 35%	2 29%	261 11%
SEP-2016	2 50%	949 41%	0 0%	295 13%	0 0%	820 35%	2 50%	263 11%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2015	13 72%	540 30%	4 22%	348 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	575 31%	8 33%	354 19%	0 0%	73 4%	2 8%	879 48%	0 0%	1 0%
MAR-2015	9 50%	599 32%	5 28%	367 20%	0 0%	69 4%	4 22%	868 47%	0 0%	2 0%
APR-2015	7 50%	627 33%	4 29%	373 20%	2 14%	67 4%	1 7%	861 45%	0 0%	2 0%
MAY-2015	11 65%	665 34%	4 24%	380 20%	1 6%	70 4%	2 12%	863 44%	0 0%	2 0%
JUN-2015	15 56%	710 35%	8 30%	394 20%	0 0%	72 4%	4 15%	875 44%	0 0%	1 0%
JUL-2015	11 58%	746 36%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	11 69%	781 38%	4 25%	413 20%	0 0%	70 3%	1 6%	854 41%	0 0%	1 0%
SEP-2015	17 85%	847 40%	1 5%	412 19%	0 0%	65 3%	2 10%	855 40%	0 0%	1 0%
OCT-2015	14 70%	889 40%	6 30%	435 20%	0 0%	65 3%	0 0%	851 39%	0 0%	1 0%
NOV-2015	15 71%	938 42%	6 29%	438 19%	0 0%	67 3%	0 0%	854 38%	0 0%	1 0%
DEC-2015	11 50%	988 43%	10 45%	445 19%	0 0%	66 3%	1 5%	841 37%	0 0%	1 0%
JAN-2016	6 55%	1021 44%	4 36%	461 20%	0 0%	67 3%	1 9%	822 35%	0 0%	1 0%
FEB-2016	7 64%	1063 45%	4 36%	469 20%	0 0%	61 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1116 46%	2 11%	482 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1155 47%	4 22%	492 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1184 47%	4 24%	495 20%	0 0%	60 2%	0 0%	798 32%	0 0%	1 0%
JUN-2016	16 62%	1218 48%	9 35%	507 20%	0 0%	58 2%	1 4%	789 31%	0 0%	1 0%
JUL-2016	14 70%	1252 49%	5 25%	519 20%	0 0%	57 2%	1 5%	785 30%	0 0%	1 0%
AUG-2016	20 59%	1306 50%	14 41%	533 20%	0 0%	55 2%	0 0%	774 29%	0 0%	1 0%
SEP-2016	19 63%	1364 50%	10 33%	541 20%	0 0%	53 2%	1 3%	781 29%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2015	2347	34.81	2123	31.49	1137	16.86	179	2.65	74	1.10	882	13.08
FEB-2015	2363	34.79	2110	31.07	1176	17.31	178	2.62	73	1.07	892	13.13
MAR-2015	2398	35.07	2112	30.89	1203	17.60	184	2.69	67	0.98	873	12.77
APR-2015	2388	34.89	2095	30.61	1237	18.07	184	2.69	67	0.98	874	12.77
MAY-2015	2392	34.76	2094	30.43	1274	18.51	179	2.60	68	0.99	875	12.71
JUN-2015	2363	34.26	2078	30.12	1321	19.15	172	2.49	72	1.04	892	12.93
JUL-2015	2370	34.22	2068	29.86	1352	19.52	171	2.47	67	0.97	897	12.95
AUG-2015	2365	34.17	2044	29.53	1381	19.95	168	2.43	70	1.01	894	12.92
SEP-2015	2323	33.56	2032	29.36	1444	20.86	168	2.43	64	0.92	891	12.87
OCT-2015	2325	33.42	2005	28.82	1491	21.43	167	2.40	64	0.92	905	13.01
NOV-2015	2315	33.03	2012	28.71	1540	21.97	160	2.28	67	0.96	914	13.04
DEC-2015	2288	32.74	1982	28.36	1580	22.61	161	2.30	62	0.89	915	13.09
JAN-2016	2286	32.78	1944	27.87	1612	23.11	158	2.27	61	0.87	913	13.09
FEB-2016	2280	32.60	1925	27.53	1669	23.87	153	2.19	59	0.84	907	12.97
MAR-2016	2266	32.38	1905	27.22	1707	24.39	154	2.20	61	0.87	905	12.93
APR-2016	2244	31.97	1895	27.00	1757	25.04	154	2.19	57	0.81	911	12.98
MAY-2016	2259	32.04	1887	26.77	1783	25.29	157	2.23	54	0.77	910	12.91
JUN-2016	2260	31.96	1877	26.55	1815	25.67	152	2.15	56	0.79	911	12.88
JUL-2016	2231	31.58	1867	26.43	1851	26.20	151	2.14	57	0.81	908	12.85
AUG-2016	2216	31.31	1840	26.00	1916	27.07	143	2.02	55	0.78	908	12.83
SEP-2016	2191	30.85	1830	25.76	1974	27.79	144	2.03	57	0.80	907	12.77

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	19	2	3	4	2	7	400
SEP-2015	32	7	1	5	2	15	505
OCT-2015	24	4	2	3	4	9	450
NOV-2015	29	5	1	6	5	10	370
DEC-2015	21	1	3	4	5	7	375
JAN-2016	16	2	3	0	5	3	380
FEB-2016	18	4	0	6	3	5	331
MAR-2016	24	4	3	4	8	5	365
APR-2016	20	2	1	2	2	9	580
MAY-2016	24	2	1	3	4	14	514
JUN-2016	34	5	5	6	10	8	380
JUL-2016	26	2	6	6	3	8	320
AUG-2016	40	2	7	6	12	13	410
SEP-2016	27	8	2	6	4	4	253

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2015	10390	2658
FEB-2015	10436	2665
MAR-2015	10475	2674
APR-2015	10495	2686
MAY-2015	10549	2710
JUN-2015	10635	2757
JUL-2015	10704	2805
AUG-2015	10770	2861
SEP-2015	10855	2916
OCT-2015	10907	2956
NOV-2015	10970	2996
DEC-2015	11016	3024
JAN-2016	11051	3055
FEB-2016	11145	3137
MAR-2016	11205	3185
APR-2016	11251	3218
MAY-2016	11311	3267
JUN-2016	11367	3298
JUL-2016	11412	3332
AUG-2016	11457	3338
SEP-2016	11488	3344

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
September 2016

N = 7103

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2016

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2016

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2016

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2016

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2016

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	34	47	22
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	70	92	50	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	330	434	253	
THOMPSON/CARIBOO/ SHUSWAP	0-19	5	5	0
	20-34	18	18	13
	35-49	55	63	37
	50+	98	146	80
Total HSDA:	176	232	130	
Total HA:		610	805	455

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	49	50	*
	35-49	174	202	*
	50+	378	544	*
Total HA:		610	805	455

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	476	640	363
Female	134	165	92

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	455	53	560	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	17	10
	5 years or more	6	5
	<5 years	11	7
	Total HSDA:	34	22
KOOTENAY BOUNDARY	10 years or more	36	25
	5 years or more	20	15
	<5 years	14	10
	Total HSDA:	70	50
OKANAGAN	10 years or more	178	127
	5 years or more	71	58
	<5 years	81	68
	Total HSDA:	330	253
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	88	60
	5 years or more	43	34
	<5 years	45	36
	Total HSDA:	176	130
Total HA:		610	455

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	319	222
	5 years or more	140	112
	<5 years	151	121
Total HA:		610	455

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries
INTERIOR Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	36	53	12	22
KOOTENAY BOUNDARY	63	112	23	40
OKANAGAN	196	683	63	249
THOMPSON/CARIBOO/SHUSWAP	126	422	37	107
Total:	421	1270	135	418

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	92

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	27	28	23
	35-49	104	116	79
	50+	181	245	150
	Total HSDA:	319	396	257
FRASER NORTH	0-19	18	18	*
	20-34	103	104	*
	35-49	358	407	*
	50+	481	746	*
	Total HSDA:	960	1275	741
FRASER SOUTH	0-19	10	10	7
	20-34	102	104	72
	35-49	363	415	297
	50+	435	642	359
	Total HSDA:	910	1171	735
Total HA:		2189	2842	1733

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	35	35	16
	20-34	232	236	175
	35-49	825	938	635
	50+	1097	1633	907
Total HA:		2189	2842	1733

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1663	2188	1350
Female	526	654	383

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1733	50	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	154	117
	5 years or more	91	80
	<5 years	74	60
	Total HSDA:	319	257
FRASER NORTH	10 years or more	467	345
	5 years or more	249	198
	<5 years	244	198
	Total HSDA:	960	741
FRASER SOUTH	10 years or more	423	335
	5 years or more	250	202
	<5 years	237	198
	Total HSDA:	910	735
Total HA:		2189	1733

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1044	797
	5 years or more	590	480
	<5 years	555	456
Total HA:		2189	1733

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	128	411	41	80
FRASER NORTH	231	1431	63	266
FRASER SOUTH	200	1195	42	337
Total:	559	3037	146	683

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	181
FRASER NORTH	623
FRASER SOUTH	502
Total:	1306

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	18
	35-49	*	*	69
	50+	*	*	185
	Total HSDA:		318	453
RICHMOND	0-19	5	5	*
	20-34	26	27	*
	35-49	44	47	*
	50+	81	121	*
	Total HSDA:		156	200
VANCOUVER	0-19	52	55	6
	20-34	412	421	321
	35-49	1542	1772	1133
	50+	2512	4178	1953
	Total HSDA:		4518	6426
Total HA:		4992	7079	3816

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	59	62	7
	20-34	458	468	362
	35-49	1673	1920	1240
	50+	2802	4629	2207
Total HA:		4992	7079	3816

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4388	6222	3370
Female	602	855	446

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3816	51	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	172	142
	5 years or more	63	59
	<5 years	83	71
	Total HSDA:	318	272
RICHMOND	10 years or more	68	52
	5 years or more	41	35
	<5 years	47	44
	Total HSDA:	156	131
VANCOUVER	10 years or more	2316	1652
	5 years or more	1199	929
	<5 years	1003	832
	Never on ART	0	0
	Total HSDA:	4518	3413
Total HA:	4992	3816	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2556	1846
	5 years or more	1303	1023
	<5 years	1133	947
	Never on ART	0	0
Total HA:		4992	3816

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	143	371	55	96
RICHMOND	42	265	14	96
VANCOUVER	546	9993	204	5308
Total:	731	10629	273	5500

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	105

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		288	400
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		108	143
SOUTH VANCOUVER ISLAND	0-19	7	7	*
	20-34	54	56	*
	35-49	211	246	*
	50+	405	629	*
	Total HSDA:		677	938
Total HA:		1073	1481	859

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	5
	20-34	88	93	65
	35-49	334	383	269
	50+	640	994	520
Total HA:		1073	1481	859

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	865	1197	697
Female	208	284	162

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	859	52	490	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	139	114
	5 years or more	65	56
	<5 years	84	69
	Total HSDA:	288	239
NORTH VANCOUVER ISLAND	10 years or more	51	42
	5 years or more	28	24
	<5 years	29	24
	Total HSDA:	108	90
SOUTH VANCOUVER ISLAND	10 years or more	341	243
	5 years or more	166	136
	<5 years	170	151
	Total HSDA:	677	530
Total HA:		1073	859

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	531	399
5 years or more	259	216
<5 years	283	244
Total HA:	1073	859

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	175	752	83	208
NORTH VANCOUVER ISLAND	120	242	44	70
SOUTH VANCOUVER ISLAND	187	1568	52	535
Total:	482	2562	179	813

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	47
NORTH VANCOUVER ISLAND	32
SOUTH VANCOUVER ISLAND	91
Total:	170

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		39	47
NORTH WEST	0-19	*	*	0
	20-34	*	*	6
	35-49	*	*	22
	50+	*	*	22
	Total HSDA:		69	101
NORTHERN INTERIOR	0-19	7	7	*
	20-34	25	27	*
	35-49	77	95	*
	50+	77	125	*
	Total HSDA:		186	254
Total HA:		294	402	211

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	36	43	*
	35-49	118	149	*
	50+	131	201	*
Total HA:		294	402	211

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	181	251	137
Female	113	151	74

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	211	49	550	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	14	7
	5 years or more	16	10
	<5 years	9	8
	Total HSDA:	39	25
NORTH WEST	10 years or more	18	8
	5 years or more	33	28
	<5 years	18	14
	Total HSDA:	69	50
NORTHERN INTERIOR	10 years or more	57	33
	5 years or more	53	45
	<5 years	76	58
	Total HSDA:	186	136
Total HA:		294	211

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	89	48
	5 years or more	102	83
	<5 years	103	80
Total HA:		294	211

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	32	59	9	12
NORTH WEST	66	145	20	26
NORTHERN INTERIOR	102	404	21	180
Total:	200	608	50	218

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	5
NORTH WEST	15
NORTHERN INTERIOR	19
Total:	39

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	29	*
	THOMPSON/CARIBOO/SHUSWAP	*	38	*
	Total HA:	48	84	35
FRASER	FRASER EAST	31	39	28
	FRASER NORTH	55	86	38
	FRASER SOUTH	74	102	62
	Total HA:	160	227	128
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	23	43	19
	RICHMOND	7	12	6
	VANCOUVER	506	794	414
	Total HA:	536	849	439
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	53	78	43
	NORTH VANCOUVER ISLAND	12	21	11
	SOUTH VANCOUVER ISLAND	37	74	29
	Total HA:	102	173	83
NORTHERN	NORTH EAST	9	11	7
	NORTH WEST	35	58	29
	NORTHERN INTERIOR	64	96	53
	Total HA:	108	165	89
Total:		954	1498	774

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	595	956	476
Female	359	542	298

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	774	49	470	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.





Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

